Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.

ABSTRACT:

Introduction

Central nervous system (CNS) metastases develop in nearly half of patients with RET fusion-positive NSCLCs and cause morbidity and mortality. The selective RET inhibitor selpercatinib treats existing intracranial disease, but no studies have investigated whether early initiation of selpercatinib is associated with decreased development of CNS metastases.

Methods

A total of 61 patients with RET fusion-positive advanced NSCLC with and without CNS metastases treated with selpercatinib on the LIBRETTO-001 trial (NCT03157128) or the LIBRETTO-201 expanded access program (NCT03906331) were identified. Cumulative incidence rates (CIRs) for CNS metastases were assessed as an event of interest; systemic progression of disease and death were considered competing risks.

SUBMITTER: Murciano-Goroff YR 

PROVIDER: S-EPMC10122712 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature